The Effect of Chronic Candesartan Therapy on the Metabolic Profile and Renal Tissue Cytokine Levels in the Obese Zucker Rat

Table 1

General physiology^†.

Treatment	Weight gain (g/14 weeks)	24-hour water intake (ml/d)	24-hour urine volume (ml/d)	24-hour urine volume (ml/g kidney weight/d)	Serum triglycerides (mg/ml)
Lean Control	124 ± 5	61 ± 3	48 ± 1	116 ± 4	1.44 ± 0.56
Lean CAN	119 ± 1	55 ± 1	42 ± 2*	104 ± 6	1.08 ± 0.07
Obese Control	232 ± 14*	73 ± 3*	51 ± 2	75 ± 3*	5.74 ± 0.95*
Obese CAN	191 ± 20*	107 ± 17^*#	69 ± 7^*#	107 ± 14^#	2.66 ± 0.41^#
Factors	Results of 2-way ANOVA for above parameters (P-values)
Body Type	<.001	<.001	<.001	.028	<.001
Treatment	.065	.074	.174	.024	.013
Interaction	.145	.016	.006	<.001	.044

^†mean ± sem,$\mathrm{\hspace{0.17em}\hspace{0.17em}}n=7$ or 8/group; ${}^{*}$indicates a significant difference from lean control; ^#indicates a significant difference between obese control and obese CAN groups, by unpaired $t$-test. In bold-  $P\text{-values}<.05$ by 2-way ANOVA (significant).